March 13th 2023
Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.
February 20th 2023
February 18th 2023
Considering Neoadjuvant Chemotherapy Options in Bladder CancerJune 17th 2016
In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.
Chemoradiation Therapy for Organ Preservation in Localized Male Urethral CarcinomaJune 15th 2016
More research is needed to define the optimal radiotherapy and chemotherapy regimen for male urethral carcinoma. However, modern chemoradiation is a feasible treatment option for motivated men with urethral carcinoma who want to preserve their organs.
Systemic Therapy for Urothelial Carcinoma: Is a Renaissance Around the Corner?June 15th 2016
Since the development of first-line cisplatin-based combination chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin almost 3 decades ago, there have not been major advances in the treatment of this disease.
POINT: Is Immediate Radical Cystectomy Justified When Non–Muscle-Invasive Bladder Cancer First Presents as High-Grade T1 Urothelial Carcinoma on Re-Resection?June 15th 2016
After a thorough repeat TURBT, disease control can be achieved with intravesical BCG and a bladder-sparing approach.
COUNTERPOINT: Is Immediate Radical Cystectomy Justified When Non–Muscle-Invasive Bladder Cancer First Presents as High-Grade T1 Urothelial Carcinoma on Re-Resection?June 15th 2016
Patients with T1 bladder cancer on re-resection achieve the best possible survival benefit by IRC and thorough pelvic lymph node dissection.
ASCO 2016: Nivolumab Effective in Metastatic Bladder Cancer, Regardless of Tumor PD-L1 StatusJune 15th 2016
Nivolumab is safe and effective in patients with metastatic bladder cancer refractory to prior lines of platinum-based chemotherapy, according to findings from the open-label, phase I/II CheckMate 032 trial.
Afatinib Promising in Urothelial Cancer Patients With ERBB3, HER2 AlterationsApril 14th 2016
Afatinib showed significant activity in a phase II trial of patients with metastatic platinum-refractory urothelial carcinoma, and patients with HER2 or ERBB3 alterations had significantly better outcomes.
Atezolizumab Granted Priority Review for Treating Advanced Bladder CancerMarch 21st 2016
The US Food and Drug Administration has accepted the priority application for atezolizumab (MPDL3280A), an investigational targeted agent for patients with locally advanced or metastatic urothelial carcinoma.
Ramucirumab Added to Docetaxel Extends PFS in Urothelial CarcinomaFebruary 29th 2016
The addition of ramucirumab to docetaxel improved progression-free survival compared with docetaxel alone in a randomized phase II trial of patients with locally advanced or metastatic urothelial carcinoma.
Checkpoint Inhibitors and Urothelial Carcinoma: The Translational ParadigmFebruary 15th 2016
The emergence of immune checkpoint inhibitors as effective cancer immunotherapy has effectively built a new “highway” connecting the promise of oncologic translational research to progress in treating advanced malignancies.
Efficacy of Low-Dose Gemcitabine, Paclitaxel, Sorafenib for Cisplatin-Resistant Urothelial CancersJanuary 15th 2016
Despite a high rate of hematologic toxicity, combined low-dose gemcitabine (Gemzar), paclitaxel, and sorafenib (Nexavar) showed promise as a well-tolerated salvage therapy in a small group of patients with cisplatin-resistant urothelial cancer.
Adjuvant RT Plus Chemo Improves Local Control in Bladder CancerJanuary 13th 2016
An Egyptian study found that bladder cancer patients who underwent radical cystectomy had better local recurrence-free survival with adjuvant radiotherapy and chemotherapy combined, compared with chemotherapy alone.
Atezolizumab Shows Promise in Advanced Urothelial CarcinomaJanuary 11th 2016
The anti-PD-L1 antibody atezolizumab showed significantly improved objective response rates compared to historic controls in a phase II study of patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy.